Observation of Initial Procalcitonin and the Clinical Course of Patients With Acute Respiratory Tract Infections
Observation of the initial Procalcitonin values and the clinical course of consecutively included patients with Acute Respiratory Tract Infections at general medical practices in greater Hannover...
Brief Summary
Official Title: “Observation of the Initial Procalcitonin Values and the Clinical Course of Patients With Acute Respiratory Tract Infections at General Medical Practices in Greater Hannover”
Observation of the initial Procalcitonin values and the clinical course of consecutively included patients with Acute Respiratory Tract Infections at general medical practices in greater Hannover.
- Study Type: Observational
- Study Design: Observational Model: Case-Only, Time Perspective: Prospective
- Study Primary Completion Date: June 2007
Detailed Clinical Trial Description
Primary endpoint: - initial Procalcitonin values of patients with Acute Respiratory Tract Infections
Secondary endpoints: - correlation of initial Procalcitonin values to classify Acute Respiratory Tract Infections - correlation of initial Procalcitonin values to subjective severity of Acute Respiratory Tract Infections - correlation of initial Procalcitonin values to antibiotic- prescriptions - correlation of initial Procalcitonin values to frequency of admission to hospital - correlation of initial Procalcitonin values to frequency of referrals (radiology, pneumology)
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- written informed consent
- all types of respiratory tract infection according to investigator´s diagnosis
Exclusion Criteria:
- pretreatment with antibiotics in the past 2 weeks
- portal hypertension
- Major surgeries or multiple trauma which require hospitalization, in previous 4 weeks
- Autoimmune disease and systemic diseases (lupus erythematodes, wegener´s disease)
- Peritoneal dialysis
- Acute treated or recently operated medullary c-cell-carcinoma, SCLC, carcinoid
- Other inflammatory diseases (e.g. urinary tract infection, pyelonephritis, pancreatitis
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Investigator Information
Lead Investigator: Hannover Medical School Other
Overall Clinical Trial Officials and Contacts
Olaf Burkhardt, PD Dr. med. Principal Investigator Medical School Hannover
Additional Information
Information obtained from ClinicalTrials.gov on February 12, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00827060
Study ID Number: HannoverPro
ClinicalTrials.gov Identifier: NCT00827060
Health Authority: Germany: Ethics Commission
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00827060
